Elaine Coustan-Smith

Coustan-Smith Elaine

Appointment(s)
  • Principal Research Scientist, Department of Paediatrics
Academic Qualifications
  • ASCP (QCYM), American Society for Clinical Pathology Board of Registry
  • Specialty in Immunology, Nottingham Trent University, United Kingdom
  • FIBMS, Specialty in Haematology, Sheffield Hallam University, United Kingdom
Research Interest(s)
  • Leukaemia Classification
  • Minimal Residual Disease
Recent Publications
  • 1. Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D. 2017 Nov. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 1(25):2348-2360. doi: 10.1182/bloodadvances.2017009928.
  • 2. Huang YJ, Coustan-Smith E, Kao HW, Liu HC, Chen SH, Hsiao CC, Yang CP, Jaing TH, Yeh TC, Kuo MC et al. 2017 Oct. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes. Journal of the Formosan Medical Association. 116(10):774-781. doi: 10.1016/j.jfma.2016.12.002.
  • 3. Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y et al.2017 Jun. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. 129(25):3304-3313. doi: 10.1182/blood-2017-01-764324.
  • 4. Pui CH, Pei D, Raimondi SC, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE et al. 2017 Feb. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia. 31(2):333-339. doi: 10.1038/leu.2016.234.